LEADS BIOLABS-B (09887) announced that, effective March 9, 2026, the company's shares will be included as a constituent of the Hang Seng Composite Index by Hang Seng Indexes Company Limited and added to the list of eligible securities for the Southbound Stock Connect program. The inclusion in both the Hang Seng Composite Index and the Stock Connect program represents significant recognition from the capital markets regarding the company's performance and value. It will permit qualified mainland Chinese investors to directly invest in the shares, which are listed on the Hong Kong Stock Exchange, through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect mechanisms. This inclusion is anticipated to broaden the company's investor base, enhance the trading liquidity of its shares, and further optimize the shareholder structure.
Comments